Colchicine Against SARS-CoV-2 Infection: What is the Evidence?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Immunology and Allergy,Rheumatology
Link
https://link.springer.com/content/pdf/10.1007/s40744-022-00425-0.pdf
Reference48 articles.
1. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–73. https://doi.org/10.1056/NEJMra2026131.
2. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–66. https://doi.org/10.1136/annrheumdis-2020-217871.
3. Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38(2):175–80.
4. Pelechas E, Drossou V, Voulgari PV, Drosos AA. Anti-rheumatic drugs for the fight against the novel coronavirus infection (SARS-CoV-2): what is the evidence? Mediterr J Rheumatol. 2020;31(Suppl 2):267–89. https://doi.org/10.31138/mjr.31.3.259.
5. Sepriano A, Kerschbaumer A, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79(6):760–70. https://doi.org/10.1136/annrheumdis-2019-216653.
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapeutics in hospitalised adult patients with COVID-19;COVID-19: An Update;2024-09-01
2. Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients;Immunity, Inflammation and Disease;2024-05
3. Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects;Rheumatology Science and Practice;2024-02-29
4. Transcriptional regulation of SARS-CoV-2 receptor ACE2 by SP1;eLife;2024-02-20
5. Antiviral history and viral targets for antiviral therapy;Microbial Genomics: Clinical, Pharmaceutical, and Industrial Applications;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3